Off-Label Use Potential With J&J’s Xarelto Not A Factor In Review, FDA Says
Executive Summary
In reviewing the approvability of Johnson & Johnson's factor Xa inhibitorXarelto (rivaroxaban), FDA must remain focused on the proposed indication - despite the inclination to factor in the risks associated with potential off-label use, Office of Oncology Drug Products Director Richard Pazdur said
You may also be interested in...
J&J Xarelto Liver Profile Key To Committee Vote; New Data Offer Assurance
The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?